DNA-Encoded Neoantigen Vaccines Induce Robust Immunity in Preclinical Models & Clinical Studies

• VB10.NEO induces strong immunity and tumour protection in preclinical studies
• Streamlined manufacturing process to reduce turnaround time
• Robust immunity in advanced cancer patients highlights DNA-encoded neoantigen vaccine potency

Speakers:

Brian Weinert

Head Director, Research Operations & of Oncology Interim Head

Nykode Therapeutics